Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has received a consensus rating of “Hold” from the twenty-one research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $115.00.

A number of brokerages have commented on ILMN. Canaccord Genuity Group upped their price objective on Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research report on Tuesday, September 2nd. TD Cowen lifted their price objective on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Cowen restated a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Finally, Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd.

Illumina Stock Up 2.1%

Shares of ILMN opened at $134.91 on Thursday. The firm has a market cap of $20.61 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 2.36 and a beta of 1.44. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina has a 52 week low of $68.70 and a 52 week high of $153.06. The firm’s 50-day simple moving average is $113.32 and its 200 day simple moving average is $102.00.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business’s revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts forecast that Illumina will post 4.51 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 500 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently bought and sold shares of ILMN. Assetmark Inc. boosted its position in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Illumina by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after buying an additional 99 shares during the period. Versant Capital Management Inc lifted its stake in Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the period. Finally, Archer Investment Corp grew its position in shares of Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.